| Literature DB >> 35820682 |
Hao Ding1,2, Yuxin Wang3, Yuan Cui1,2, Zhike Chen1,2, Yu Li1,2, Jian Yang1,2, Yang Yang4, Tengfei Chen1,2, Dian Xia5, Chang Li1,2, Chun Xu1,2, Cheng Ding1,2, Jun Zhao1,2.
Abstract
BACKGROUND: Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer and has a poor prognosis. RBR E3 ubiquitin ligases are a special class of E3 ubiquitin ligases which contain three zinc-bing domains that catalyze ubiquitin to substrate proteins. The RBR family of E3 ubiquitin ligases has been reported in various human malignancies, but the roles of RBR E3 ubiquitin ligases in LUAD remain unclear.Entities:
Keywords: RBR E3 ubiquitin ligases; bioinformatic analysis; biomarkers; lung adenocarcinoma; prognosis
Mesh:
Substances:
Year: 2022 PMID: 35820682 PMCID: PMC9436683 DOI: 10.1111/1759-7714.14577
Source DB: PubMed Journal: Thorac Cancer ISSN: 1759-7706 Impact factor: 3.223
FIGURE 1Identification of differentially expressed RBR E3 ubiquitin ligases between LUAD and normal controls in the TCGA‐LUAD database. (a) The correlation among RBR E3 ubiquitin ligases. (b–d) Heatmap and box plots display the distribution of RBR E3 ubiquitin ligases expression between LUAD and normal controls in the TCGA cohort
FIGURE 2The prognostic value of the clinicopathological factors for the four potential biomarkers. (a–d) Effect of the clinicopathological factors of ARIH2, RNF144B, RNF216, RNF217 on OS using the Kaplan–Meier plotter. * p < 0.05; ** p < 0.01; ***p < 0.001
FIGURE 3Relationship between four potential biomarkers mRNA expression levels and clinicopathological characteristics in LUAD. (a) The relationship between mRNA expression levels of these four RBR E3 ubiquitin ligases and patients' pathological stage. (b–d) The relationship between mRNA expression levels of these four RBR E3 ubiquitin ligases and patients' TNM stage. * p < 0.05; ** p < 0.01; ***p < 0.001
FIGURE 4Differential expressions of four potential biomarkers in NSCLC cell lines and one normal lung epithelial cell line. A549, human lung adenocarcinoma cell line; H1650, human lung adenocarcinoma cell line; H460, human large cell lung cancer cell line; HBE, normal human bronchial epithelial cells. *p<0.05, **p<0.01, ***p<0.001.
FIGURE 5Genetic mutations and their association with LUAD prognosis of ARIH2, RNF144B, RNF216, and RNF217 genes. (a) OncoPrint of c‐BioPortal showed the mutation types and proportions of these four genes, respectively from TCGA samples. (b) Cancer types summary of c‐BioPortal specifically showed the types of mutations and their proportions contained in each cancer. (c) Overall survival and disease‐free survival in cases with/without these four genes alterations
FIGURE 6Screening of four RBR E3 ubiquitin ligases co‐expressed genes by Linkedomics. (a) Volcano plot of ARIH2 co‐expressed genes. (b) Volcano plot of RNF144B co‐expressed genes. (c) Volcano plot of RNF216 co‐expressed genes. (d) Volcano plot of RNF217 co‐expressed genes. (e) Top 50 positively and top 50 negatively correlated genes of ARIH2. (f) Top 50 positively and top 50 negatively correlated genes of RNF144B. (g) Top 50 positively and top 50 negatively correlated genes of RNF216. (h) Top 50 positively and top 50 negatively correlated genes of RNF217
FIGURE 7GSEA enrichment of four altered EBR E3 ubiquitin ligases in the TCGA LUAD cohort. (a‐d) The bubble map shows the top 15 GSEA‐enriched gene sets of ARIH2, RNF144B, RNF216, RNF217. (e‐h) GSEA enrichment analyses of co‐expressed genes indicating an association of ARIH2, RNF144B, RNF216, RNF217 with NADH dehydrogenase complex assembly. GSEA: Gene Set Enrichment Analysis
TOP 30 GO functional enrichment analysis of four potential biomarkers and their interacting genes in LUAD
| GO | Category | Description |
| Count |
|---|---|---|---|---|
| GO:0032480 | GO biological processes | Negative regulation of type I interferon production | 3.32857E‐12 | 7 |
| GO:0043161 | GO biological processes | Proteasome‐mediated ubiquitin‐dependent protein catabolic process | 1.55751E‐11 | 12 |
| GO:0010498 | GO biological processes | Proteasomal protein catabolic process | 6.99509E‐11 | 12 |
| GO:1903052 | GO biological processes | positive regulation of proteolysis involved in cellular protein catabolic process | 7.59907E‐11 | 8 |
| GO:0032479 | GO biological processes | Regulation of type I interferon production | 1.1264E‐10 | 8 |
| GO:0032606 | GO biological processes | Type I interferon production | 1.27871E‐10 | 8 |
| GO:1903364 | GO biological processes | Positive regulation of cellular protein catabolic process | 2.62631E‐10 | 8 |
| GO:0045732 | GO biological processes | Positive regulation of protein catabolic process | 2.71839E‐10 | 9 |
| GO:0032648 | GO biological processes | Regulation of interferon‐beta production | 4.57194E‐10 | 6 |
| GO:0032608 | GO biological processes | Interferon‐beta production | 5.90346E‐10 | 6 |
| GO:2000060 | GO biological processes | Positive regulation of ubiquitin‐dependent protein catabolic process | 6.41312E‐10 | 7 |
| GO:1901800 | GO biological processes | Positive regulation of proteasomal protein catabolic process | 1.21734E‐09 | 7 |
| GO:0000209 | GO biological processes | Protein polyubiquitination | 7.06565E‐09 | 9 |
| GO:1903050 | GO biological processes | Regulation of proteolysis involved in cellular protein catabolic process | 7.58462E‐09 | 8 |
| GO:0032436 | GO biological processes | Positive regulation of proteasomal ubiquitin‐dependent protein catabolic process | 1.15354E‐08 | 6 |
| GO:2000058 | GO biological processes | Tegulation of ubiquitin‐dependent protein catabolic process | 1.50784E‐08 | 7 |
| GO:1903362 | GO biological processes | Regulation of cellular protein catabolic process | 2.32282E‐08 | 8 |
| GO:0045862 | GO biological processes | Positive regulation of proteolysis | 2.45604E‐08 | 9 |
| GO:0042176 | GO biological processes | Regulation of protein catabolic process | 4.19396E‐08 | 9 |
| GO:0061136 | GO biological processes | Regulation of proteasomal protein catabolic process | 6.22337E‐08 | 7 |
| GO:0016579 | GO biological processes | Protein deubiquitination | 6.65789E‐08 | 8 |
| GO:0070646 | GO biological processes | Protein modification by small protein removal | 1.0164E‐07 | 8 |
| GO:0009896 | GO biological processes | Positive regulation of catabolic process | 1.06644E‐07 | 9 |
| GO:0000151 | GO cellular components | Ubiquitin ligase complex | 2.67001E‐08 | 8 |
| GO:0004842 | GO molecular functions | Ubiquitin‐protein transferase activity | 3.61547E‐19 | 17 |
| GO:0019787 | GO molecular functions | Ubiquitin‐like protein transferase activity | 1.05714E‐18 | 17 |
| GO:0061630 | GO molecular functions | Ubiquitin protein ligase activity | 5.77594E‐13 | 11 |
| GO:0061659 | GO molecular functions | Ubiquitin‐like protein ligase activity | 8.94046E‐13 | 11 |
| GO:0031625 | GO molecular functions | Ubiquitin protein ligase binding | 2.82069E‐10 | 10 |
| GO:0044389 | GO molecular functions | Ubiquitin‐like protein ligase binding | 5.06901E‐10 | 10 |
FIGURE 8Functional enrichment analysis of these four potential biomarkers and their interacting genes. Gene Ontology (GO) functional enrichment was analyzed by R package: clusterProfiler. Protein domain of interacting genes were performed using Funrich (version 3.1.3). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and their interactors were performed using DAVID. (a) TOP 20 GO Biological Processes, (b) Protein domain of interacting genes, (c) KEGG pathway enrichment analysis of target genes
KEGG functional enrichment analysis of four potential biomarkers and their interacting genes in LUAD
| Term | Category | Description | Count | % |
|
|---|---|---|---|---|---|
| hsa04622 | KEGG pathway | RIG‐I‐like receptor signaling pathway | 6 | 15.38461538 | 3.78084E‐07 |
| hsa05169 | KEGG pathway | Epstein–Barr virus infection | 5 | 12.82051282 | 0.000145329 |
| hsa05164 | KEGG pathway | Influenza A | 5 | 12.82051282 | 0.00056724 |
| hsa04064 | KEGG pathway | NF‐kappa B signaling pathway | 4 | 10.25641026 | 0.00097147 |
| hsa05160 | KEGG pathway | Hepatitis C | 4 | 10.25641026 | 0.003290683 |
| hsa05168 | KEGG pathway | Herpes simplex infection | 4 | 10.25641026 | 0.008033343 |
| hsa04623 | KEGG pathway | Cytosolic DNA‐sensing pathway | 3 | 7.692307692 | 0.00940191 |
| hsa05162 | KEGG pathway | Measles | 3 | 7.692307692 | 0.037297812 |
| hsa05161 | KEGG pathway | Hepatitis B | 3 | 7.692307692 | 0.043649238 |